Viewing Study NCT02034006

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 4:03 PM
Ignite Modification Date: 2026-03-02 @ 3:43 PM
Study NCT ID: NCT02034006
Status: COMPLETED
Last Update Posted: 2019-02-18
First Post: 2014-01-09
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Choroidal Neovascularization Secondary to Pathologic Myopia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None pathological myopia View
None choroidal neovascularization View
None ranibizumab View
None mono-bilateral View
None poor visual acuity View
None retinal disease View
None eye disease View
None Angiogenesis Inhibitors View
None Angiogenesis Modulating Agents View